Literature DB >> 30475320

Bilateral Developmental Dysplasia of the Hip: Does Closed Reduction Have a Role in Management? Outcome of Closed and Open Reduction in 92 Hips.

Sally J Tennant1, Aresh Hashemi-Nejad, Peter Calder, Deborah M Eastwood.   

Abstract

BACKGROUND: Bilateral developmental dysplasia of the hip (DDH) is believed to have a worse outcome than unilateral DDH with the optimal treatment unclear. To define indications for treatment we report a retrospective series of 92 hips (46 patients) who underwent closed reduction (CR) and/or open reduction (OR).
METHODS: A total of 58 hips in 29 patients underwent attempted CR using our standardized protocol. In the same 12 year time period, 54 hips in 27 patients underwent an OR. Outcome measures included resolution of acetabular dysplasia, need for further surgery, development of osteonecrosis (ON), and modified Severin Grade.
RESULTS: CR was successful in 57% of hips; in this group secondary surgery was required in 15% and ON was seen in 12%. In the OR group, 11% failed to stabilize and required further early surgery: ON rate was 15% overall, and secondary surgery was required in 5%. In Tonnis 2/3 hips younger than 2 years, Severin grading was comparable following CR and OR, with 92% and 90% graded as Severin 1, respectively. The rate of significant ON was higher after CR in Tonnis 2/3 hips (12%) than after OR (0%). Overall, Tonnis 4 hips did badly: 94% failed CR and following OR, further surgery for redislocation/residual dysplasia was required in 21%.
CONCLUSIONS: CR can be successful in Tonnis 2/3 bilateral hips, with acceptable rates of secondary surgery, ON, and Severin grading, the latter equivalent to open reduction. Importantly, persisting with casting of a unilateral dislocation, to allow the contra-lateral hip to stabilize, does not have an adverse effect. CR is not advised in Tonnis 4 bilateral hips. Parents should be counseled that the outcome of surgery for bilateral hips is not as good as for unilateral DDH, particularly for Tonnis 4 hips which are more difficult to stabilize and more likely to require supplementary surgery even after open reduction. LEVEL OF EVIDENCE: Level IV-Therapeutic Study.

Entities:  

Mesh:

Year:  2019        PMID: 30475320     DOI: 10.1097/BPO.0000000000001297

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  6 in total

1.  Retrospective Comparison of Outcomes Between Closed and Open Reduction for Developmental Dysplasia of the Hip in Children Aged 6-24 Months.

Authors:  Shuyu Ma; Weizheng Zhou; Lianyong Li; Enbo Wang; Lijun Zhang; Qiwei Li
Journal:  Indian J Orthop       Date:  2022-07-05       Impact factor: 1.033

2.  Efficacy of closed reduction for developmental dysplasia of the hip: midterm outcomes and risk factors associated with treatment failure and avascular necrosis.

Authors:  Ge Zhang; Ming Li; Xiangyang Qu; Yujiang Cao; Xing Liu; Cong Luo; Yuan Zhang
Journal:  J Orthop Surg Res       Date:  2020-12-02       Impact factor: 2.359

3.  Narrative Review of Complications Following DDH Treatment.

Authors:  Raghav Badrinath; Caitlin Orner; James D Bomar; Vidyadhar V Upasani
Journal:  Indian J Orthop       Date:  2021-10-23       Impact factor: 1.251

4.  Short versus Long-Leg Hip Spica After Closed Reduction in Developmental Dysplasia of the Hip: A Retrospective Comparative Study.

Authors:  Mohamad S Yasin; Mohammed S Alisi; Yazan S Hammad; Omar Q Samarah; Freih O Abu Hassan
Journal:  Orthop Res Rev       Date:  2022-03-24

5.  Risk factors for failed closed reduction in dislocated developmental dysplastic hips.

Authors:  Sebastian Gottfried Walter; Christoph Hans-Jürgen Endler; Anna Christina Remig; Julian A Luetkens; Rahel Bornemann; Richard Placzek
Journal:  Int Orthop       Date:  2020-06-01       Impact factor: 3.075

6.  Surgical management of the congenital dislocation of the knee and hip in children presented after six months of age.

Authors:  Amrath Raj B K; Kumar Amerendra Singh; Hitesh Shah
Journal:  Int Orthop       Date:  2020-08-08       Impact factor: 3.075

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.